Male Infertility – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Male Infertility Market Outlook

Thelansis’s “Male Infertility Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Male Infertility treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Male Infertility Overview

Fertility refers to the ability to achieve a clinical pregnancy, while infertility is a medical condition characterized by the inability to establish a clinical pregnancy within 12 months of regular and unprotected sexual intercourse or due to a person's impaired reproductive capacity as an individual or with their partner. The causes of male infertility can be broadly classified based on their underlying etiology. These causes include endocrine disorders (typically resulting from hypogonadism), accounting for approximately 2% to 5% of cases; sperm transport disorders (e.g., vasectomy), accounting for 5%. Primary testicular defects (including abnormal sperm parameters without an identifiable cause) account for 65% to 80%, and idiopathic cases (where an infertile male has normal sperm and semen parameters) account for 10% to 20%. Male infertility can also be categorized based on potential medical interventions to aid conception. Untreatable male sterility encompasses conditions such as primary seminiferous tubular failure, Sertoli cell-only syndrome, and bilateral orchiectomy, accounting for 12% of cases. Treatable causes of male infertility, accounting for 18% of cases, include obstructive azoospermia, ejaculatory duct and prostatic midline cysts, gonadotropin deficiency, sexual function disorders, sperm autoimmunity, varicoceles, and reversible toxin effects. Untreatable male infertility, accounting for 70% of cases, includes oligozoospermia, asthenozoospermia, teratozoospermia, and normospermia with functional defects, requiring assisted reproductive techniques for successful reproduction. Various conditions and disorders can contribute to or cause male infertility. Some common causes include adult growth hormone deficiency, 5-Alpha reductase deficiency, androgen receptor gene polymorphisms, brain damage from tumors or trauma, bilateral testicular torsion, celiac disease, chemotherapy, chromosomal abnormalities, and congenital adrenal hyperplasia. Complications often arise from psychological distress, stress, and marital issues. The choice of treatment for male infertility depends on the underlying cause. Common treatment options include medication (administered to enhance sperm production, correct hormone imbalances, treat sperm-affecting infections, or boost testosterone levels), varicocele repair (a minor surgical procedure to address a physical condition that can raise testicular temperature and impact sperm quality), surgery, microsurgical fertilization procedures, and assisted reproductive technologies like in vitro fertilization (IVF).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: